PATENT CLAIM ANALYSIS

Application Number: 15778897
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "086000"]

Abstract:
The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

Claim (Index 7):
The compound, or the pharmaceutically acceptable salt, solvate or prodrug thereof according to  claim 5 , wherein R 2  and R 3  are selected from deuterium, R 1,  R 6 , R 7 , R 8 , R 9 , R 10  and R 11  are selected from hydrogen, and R 4  and R 5  are each independently selected from hydrogen or deuterium.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 93.0
- Lexical Diversity: 1.76596
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14652705', '15537002', '10689381', '14786069', '14391386']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7983047619150456
- 35 USC 102 Novelty (BERT): 0.5022421823848225
- Combined Prediction Score: 0.7686985039620233
- Mean Citation Score: 266.572804
- Max Citation Score: 271.7428
- Similarity Product: 214.2563564537525

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test